Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma

Cancer

Volumn 118, Issue 5, 2012, Pages 1268-1275

  Minner, Sarah ^a   Rump, Dorothea ^a   Tennstedt, Pierre ^a   Simon, Ronald ^a   Burandt, Eike ^a   Terracciano, Luigi ^b   Moch, Holger ^c   Wilczak, Waldemar ^a   Bokemeyer, Carsten ^a   Fisch, Margit ^a   Sauter, Guido ^a   Eichelberg, Christian ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

copy number changes; epidermal growth factor receptor; renal cell carcinoma; tissue microarray

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADVANCED CANCER; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CLEAR CELL CARCINOMA; COPY NUMBER VARIATION; DISOMY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EXON; EXON 18; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LYMPH NODE; MAJOR CLINICAL STUDY; ONCOCYTOMA; OVERALL SURVIVAL; PAPILLARY CARCINOMA; POLYSOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TRISOMY;

CARCINOMA, RENAL CELL; CHROMOSOME ABERRATIONS; DNA MUTATIONAL ANALYSIS; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KIDNEY NEOPLASMS; MUTATION; NEOPLASM STAGING; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE ARRAY ANALYSIS;

EID: 84857358303     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26436     Document Type: Article

References (35)

1. Yarden Y, Sliwkowski MX,. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2: 127-137. (Pubitemid 33674041)
2. Hynes NE, Lane HA,. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005; 5: 341-354. (Pubitemid 40637826)
3. Stumm G, Eberwein S, Rostock-Wolf S, et al. Concomitant overexpression of the EGFR and erbB-2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis. Int J Cancer. 1996; 69: 17-22. (Pubitemid 26083265)
4. Moch H, Sauter G, Buchholz N, et al. Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma. Hum Pathol. 1997; 28: 1255-1259. (Pubitemid 27492824)
5. Amare Kadam PS, Varghese C, Bharde SH, et al. Proliferating cell nuclear antigen and epidermal growth factor receptor (EGFr) status in renal cell carcinoma patients with polysomy of chromosome 7. Cancer Genet Cytogenet. 2001; 125: 139-146. (Pubitemid 32448058)
6. Moch H, Sauter G, Gasser TC, et al. EGF-r gene copy number changes in renal cell carcinoma detected by fluorescence in situ hybridization. J Pathol. 1998; 184: 424-429. (Pubitemid 28179903)
7. Merseburger AS, Hennenlotter J, Simon P, et al. Membranous expression and prognostic implications of epidermal growth factor receptor protein in human renal cell cancer. Anticancer Res 25 (3B): 1901-1907, 2005. (Pubitemid 40904584)
8. Cohen D, Lane B, Jin T, et al. The prognostic significance of epidermal growth factor receptor expression in clear-cell renal cell carcinoma: a call for standardized methods for immunohistochemical evaluation. Clin Genitourin Cancer. 2007; 5: 264-270. (Pubitemid 46867362)
9. Ishikawa J, Maeda S, Umezu K, Sugiyama T, Kamidono S,. Amplification and overexpression of the epidermal growth factor receptor gene in human renal-cell carcinoma. Int J Cancer. 1990; 45: 1018-1021. (Pubitemid 20201568)
10. Ljungberg B, Gafvels M, Damber JE,. Epidermal growth factor receptor gene expression and binding capacity in renal cell carcinoma, in relation to tumor stage, grade and DNA ploidy. Urol Res. 1994; 22: 305-308. (Pubitemid 24369386)
11. Hofmockel G, Riess S, Bassukas ID, Dammrich J,. Epidermal growth factor family and renal cell carcinoma: expression and prognostic impact. Eur Urol. 1997; 31: 478-484. (Pubitemid 27234641)
12. Uhlman DL, Nguyen P, Manivel JC, et al. Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis. Clin Cancer Res. 1995; 1: 913-920.
13. Baselga J, Arteaga CL,. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol. 2005; 23: 2445-2459. (Pubitemid 47050835)
14. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-2139. (Pubitemid 38637993)
15. Fuhrman SA, Lasky LC, Limas C,. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982; 6: 655-663. (Pubitemid 13234762)
16. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005; 97: 643-655. (Pubitemid 40812628)
17. de Paulsen N, Brychzy A, Fournier MC, et al. Role of transforming growth factor-alpha in von Hippel-Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci U S A. 2001; 98: 1387-1392. (Pubitemid 32165508)
18. Kanematsu T, Yano S, Uehara H, Bando Y, Sone S,. Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients. Oncol Res. 2003; 13: 289-298.
19. Magkou C, Nakopoulou L, Zoubouli C, et al. Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas [serial online]. Breast Cancer Res. 2008; 10: R49.
20. Noordhuis MG, Eijsink JJ, Ten Hoor KA, et al. Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer. Clin Cancer Res. 2009; 15: 7389-7397.
21. Hammarsten P, Karalija A, Josefsson A, et al. Low levels of phosphorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients. Clin Cancer Res. 2010; 16: 1245-1255.
22. Wolf M, Mousses S, Hautaniemi S, et al. High-resolution analysis of gene copy number alterations in human prostate cancer using CGH on cDNA microarrays: impact of copy number on gene expression. Neoplasia. 2004; 6: 240-247. (Pubitemid 38657080)
23. Dehan E, Ben-Dor A, Liao W, et al. Chromosomal aberrations and gene expression profiles in non-small cell lung cancer. Lung Cancer. 2007; 56: 175-184. (Pubitemid 46613918)
24. Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 1 23: 6829-6837, 2005.
25. Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst. 2005; 97: 880-887. (Pubitemid 41417939)
26. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group study. J Clin Oncol. 2005; 23: 6838-6845.
27. El-Hariry I, Powles T, Lau MR, et al. Amplification of epidermal growth factor receptor gene in renal cell carcinoma. Eur J Cancer. 2010; 46: 859-862.
28. Jermann M, Stahel RA, Salzberg M, et al. A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer Chemother Pharmacol. 2006; 57: 533-539. (Pubitemid 43087597)
29. Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 1 22: 3003-3015, 2004. (Pubitemid 41103711)
30. Asakuma J, Sumitomo M, Asano T, Hayakawa M,. Modulation of tumor growth and tumor induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 in renal cell carcinoma. J Urol. 2004; 171 (2 pt 1): 897-902. (Pubitemid 38090529)
31. Gordon MS, Hussey M, Nagle RB, et al. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol. 2009; 27: 5788-5793.
32. Bukowski RM, Kabbinavar FF, Figlin RA, et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol. 2007; 25: 4536-4541. (Pubitemid 350035309)
33. Dawson NA, Guo C, Zak R, et al. A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin Cancer Res. 2004; 10: 7812-7819. (Pubitemid 39587518)
34. Sakaeda T, Okamura N, Gotoh A, et al. EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients. Pharm Res. 2005; 22: 1757-1761. (Pubitemid 41355916)
35. Szymanska K, Moore LE, Rothman N, et al. TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe. Cancer Lett. 2010; 293: 92-98.